

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement*



**Genor Biopharma Holdings Limited**  
**嘉和生物藥業(開曼)控股有限公司**  
*(incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 6998)**

**CHANGE OF COMPANY SECRETARY,  
AUTHORISED REPRESENTATIVE AND AGENT FOR THE SERVICE OF  
PROCESS IN HONG KONG  
AND  
CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG**

The board of directors (the “**Board**”) of Genor Biopharma Holdings Limited (the “**Company**”) announces that Ms. Ho Siu Pik (“**Ms. Ho**”) has tendered her resignation as (i) the company secretary of the Company (the “**Company Secretary**”); (ii) the authorised representative of the Company (the “**Authorised Representative**”) pursuant to Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”); and (iii) the authorised representative to accept service of process and notices on behalf of the Company in Hong Kong (the “**Process Agent**”) under Rule 19.05(2) of the Listing Rules and under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) with effect from 30 June 2022. Ms. Ho has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board further announces that Mr. Ip Tak Wai (“**Mr. Ip**”) has been appointed as the Company Secretary, the Authorised Representative and the Process Agent with effect from 30 June 2022.

Mr. Ip is a director of Tricor Services Limited, a global professional services provider specializing in integrated business, corporate and investor services. Mr. Ip has over 17 years of experience in corporate governance, compliance and share registration profession. He has been providing corporate secretarial and compliance services, share registration and IPO services to Hong Kong listed companies as well as multinational, private and offshore companies.

Mr. Ip is a Chartered Secretary, a Chartered Governance Professional and a fellow of both The Hong Kong Chartered Governance Institute (formerly known as The Hong Kong Institute of Chartered Secretaries) and The Chartered Governance Institute. Mr. Ip obtained a bachelor’s degree in Integrated Business Administration from The Chinese University of Hong Kong and a master degree in Professional Accounting and Corporate Governance from City University of Hong Kong.

The Board would like to take this opportunity to express its sincere gratitude to Ms. Ho for her valuable contribution to the Company during her term of service and also extend its warm welcome to Mr. Ip on his appointment.

The Board further announces that the principal place of business of the Company in Hong Kong has been changed to 5/F, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong with effect from 30 June 2022.

By order of the Board  
**Genor Biopharma Holdings Limited**  
**Dr. Guo Feng**  
*Chief Executive Officer and Chairman*

Hong Kong, 30 June 2022

*As at the date of this announcement, the Board comprises Dr. GUO Feng (Chief Executive Officer and Chairman) as an executive director; Dr. LYU Dong, Mr. CHEN Yu and Dr. NI Lin as non-executive directors; and Mr. ZHOU Honghao, Mr. FUNG Edwin and Mr. CHEN Wen as independent non-executive directors.*